HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Khosravan, R. Articles by Vernillet, L. Search for Related Content PubMed PubMed Citation Articles by Khosravan, R. Articles by Vernillet, L.

Pharmacokinetic Interactions of Concomitant Administration of Febuxostat and NSAIDs

From TAP Pharmaceutical Products, Inc, Lake Forest, Illinois.

To evaluate the effect of febuxostat on the pharmacokinetics of indomethacin and naproxen and vice versa, 2 multiple-dose, 3-period crossover studies were performed in healthy subjects. In study 1, subjects received febuxostat 80 mg once daily, indomethacin 50 mg twice daily, or both. In study 2, subjects received febuxostat 80 mg, naproxen 500 mg twice daily, or both. Twenty-four-hour blood samples were collected on day 5 in study 1 and day 7 in study 2. In study 1, 90% confidence intervals of geometric mean ratios for maximum plasma concentration (C_max) and area under the curve (AUC) were within the 0.80 to 1.25 no-effect range for febuxostat and indomethacin. In study 2, 90% confidence intervals for febuxostat C_max and AUC extended above that range, with increases of 28% and 40% in C_max and AUC₂₄, respectively. However, 90% confidence intervals for naproxen C_max and AUC were within the 0.80 to 1.25 range. Febuxostat had no effect on the plasma pharmacokinetics of indomethacin and naproxen. Similarly, indomethacin had no effect on the plasma pharmacokinetics of febuxostat. Although naproxen caused an increase in plasma exposure to febuxostat, this increase is not expected to be clinically significant. Therefore, based on the plasma pharmacokinetic data in healthy subjects, febuxostat may be administered with indomethacin or naproxen with no dose adjustments for febuxostat, indomethacin, or naproxen.

Key Words: Febuxostat • drug-drug interaction • NSAID • indomethacin • naproxen • pharmacokinetics

This article has been cited by other articles:

				L. F. Zerbini, A. Czibere, Y. Wang, R. G. Correa, H. Otu, M. Joseph, Y. Takayasu, M. Silver, X. Gu, K. Ruchusatsawat, et al. A Novel Pathway Involving Melanoma Differentiation Associated Gene-7/Interleukin-24 Mediates Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis and Growth Arrest of Cancer Cells Cancer Res., December 15, 2006; 66(24): 11922 - 11931. [Abstract] [Full Text] [PDF]

				S. P Bruce Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout Ann. Pharmacother., December 1, 2006; 40(12): 2187 - 2194. [Abstract] [Full Text] [PDF]